Fig. 1
From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
Cost-effectiveness Acceptability Curves between Treatments. Olysio + Sovaldi versus Harvoni for Genotype 1 (Subfigure 1); Viekira Pak versus Harvoni for Genotype 1 (Subfigure 2); Sofosbuvir + Peginterferon + Ribavirin versus Harvoni for Genotype 1 (Subfigure 3); Two-phase of 24 + 12 versus Peginterferon + Ribavirin for Genotype 2 (Subfigure 4); Two-phase of 24 + 16 versus Two-phase of 24 + 12 for Genotype 2 (Subfigure 5); Sofosbuvir + Ribavirin versus Two-phase of 24 + 16 for Genotype 2 (Subfigure 6); Two-phase of 24 + 12 versus Peginterferon + Ribavirin for Genotype 3 (Subfigure 7); Two-phase of 24 + 16 versus Two-phase of 24 + 12 for Genotype 3 (Subfigure 8); Sofosbuvir + Ribavirin versus Two-phase of 24 + 16 for Genotype 3 (Subfigure 9)